IRIS PubliCatt

Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.142
NA - Nord America 5.361
AS - Asia 1.956
AF - Africa 30
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 11
Totale 14.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.315
DE - Germania 3.494
SE - Svezia 1.112
CN - Cina 834
IT - Italia 684
SG - Singapore 557
UA - Ucraina 514
IE - Irlanda 333
FR - Francia 277
GB - Regno Unito 230
ID - Indonesia 200
FI - Finlandia 169
IN - India 134
TR - Turchia 117
RU - Federazione Russa 115
PL - Polonia 52
BE - Belgio 38
CA - Canada 35
IR - Iran 30
JP - Giappone 25
AU - Australia 22
NL - Olanda 20
CI - Costa d'Avorio 18
CZ - Repubblica Ceca 17
HK - Hong Kong 17
ES - Italia 16
EU - Europa 15
CH - Svizzera 13
PT - Portogallo 11
KR - Corea 10
AT - Austria 9
IL - Israele 9
BR - Brasile 8
LT - Lituania 8
EG - Egitto 6
HU - Ungheria 6
MX - Messico 6
BG - Bulgaria 4
BZ - Belize 4
MO - Macao, regione amministrativa speciale della Cina 4
RO - Romania 4
RS - Serbia 4
GR - Grecia 3
IQ - Iraq 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AR - Argentina 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BT - Bhutan 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
UG - Uganda 1
VE - Venezuela 1
VN - Vietnam 1
Totale 14.542
Salva come PNG Salva come JPEG
Città #
Chandler 1.277
Cologne 1.211
Singapore 447
Ashburn 439
Dublin 325
Jacksonville 321
San Mateo 264
Jakarta 199
Nanjing 171
New York 165
Ann Arbor 147
Wilmington 141
Milan 138
Dearborn 134
Cattolica 123
Nürnberg 119
Beijing 113
Boston 113
Munich 107
Princeton 107
Izmir 100
Chicago 82
Marseille 82
Moscow 73
Rome 68
Houston 62
Bremen 61
Essen 61
Helsinki 61
Nanchang 60
Woodbridge 59
Lawrence 57
Seattle 56
Los Angeles 55
Redwood City 53
Fairfield 44
Hangzhou 43
Lancaster 43
Boardman 39
Pune 39
Norwalk 38
Brussels 35
Kraków 35
Mountain View 35
Hebei 34
Shenyang 31
Tianjin 27
Jiaxing 26
University Park 26
Augusta 24
Kunming 24
Changsha 23
Leawood 23
Shanghai 23
Zhengzhou 19
Abidjan 18
Detroit 18
Guangzhou 18
Fremont 16
Jinan 16
Toronto 16
London 15
Washington 15
Hong Kong 14
San Jose 14
Andover 13
Kish 13
Redmond 13
Warsaw 13
Falkenstein 12
Ottawa 11
Zurich 10
Brno 9
Costa Mesa 9
Edinburgh 9
Hefei 9
Tokyo 9
Ardabil 8
Busto Arsizio 8
Cagliari 8
Campagna 8
Istanbul 8
Lappeenranta 8
Seoul 8
Simi Valley 8
Amsterdam 7
Atlanta 7
Cambridge 7
Frankfurt am Main 7
Lanzhou 7
Ningbo 7
Paris 7
Santa Clara 7
Vienna 7
Wuhan 7
Buffalo 6
Changchun 6
Columbus 6
Indiana 6
Las Vegas 6
Totale 8.136
Salva come PNG Salva come JPEG
Nome #
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management 1.304
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 320
A) Infliximab in the treatment of steroid-dependent ulcerative colitis. 257
A) Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease 211
13C-methionine breath tests for mitochondrial liver function assessment. 203
Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms 195
13C-breath tests in the study of microsomal liver function 194
Growth hormone in inflammatory bowel disease 183
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study 173
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 154
134C-breath tests in the study of mitochondrial liver function 153
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 151
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 145
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 144
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 141
13C-breath tests in the study of microsomial liver function 140
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 138
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 136
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 131
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 129
13C-methionine breath tests for mitochondrial liver function assessment 125
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 125
A) Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 121
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 121
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 117
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 115
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 114
13C-breath tests in the study of mitochondrial liver function 113
Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test 113
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 108
Levofloxacin based regimens for the eradication of Helicobacter pylori 107
Ileal Crohn's disease: CEUS determination of activity 107
ag) Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. 106
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 104
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 102
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis 99
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 99
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 98
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study 97
-Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? 97
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 96
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 96
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 95
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 94
Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update 92
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 92
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 88
Probiotics and Helicobacter pylori eradication 88
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 88
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. 88
Helicobacter pylori treatment: a role for probiotics? 87
A novel pathogenic role for microvasculature in inflammatory bowel disease. 86
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 84
A) Study of liver function in healthy elderly subjects using the 13C-methacetin breath test 82
[Helicobacter pylori and gastric carcinoma] 81
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 79
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 79
Infliximab in Crohn's disease: early and long-term treatment. 79
Gender affects 13C-ketoisocaproic acid breath test 79
Management of perianal fistulas in Crohn's disease: an up-to-date review 78
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 78
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 77
Review article: breath testing for human liver function assessment. 75
Mucosal healing in ulcerative colitis: surveillance or colectomy? 72
Clinical trials in ulcerative colitis: a historical perspective 72
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 72
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 72
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 71
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 71
Biological therapies for inflammatory bowel disease: research drives clinics. 69
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 69
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 69
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 69
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 67
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis 67
A) Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation 67
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 67
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 67
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 67
Adalimumab in active ulcerative colitis: a "real-life" observational study 66
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease 65
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 65
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 65
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 65
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease 64
Reply to Dr. Joob et al.'s letter 64
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease 63
Inducing remission of ulcerative colitis: are clinicians better equipped than ever? 63
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 61
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 61
Frontiers in drug research and development for inflammatory bowel disease 60
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 60
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 60
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 59
Italian IBD Patients Coping With Covid-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-care 59
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 59
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 58
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 58
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 58
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 58
Totale 11.150
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020682 0 0 0 0 0 0 130 80 103 57 179 133
2020/20211.103 71 106 18 132 132 44 94 28 149 64 242 23
2021/20221.510 97 120 28 178 43 48 23 246 45 94 269 319
2022/20233.459 421 441 239 540 266 394 163 302 413 98 117 65
2023/20243.061 79 490 61 108 88 270 95 1.196 214 81 179 200
2024/2025999 67 107 304 82 285 146 8 0 0 0 0 0
Totale 14.765